Agilent Technologies, Inc. · NYSE:A

Agilent Technologies — Q3 2023 Earnings Presentation

9 slides from Agilent Technologies's earnings presentation, Aug 15, 2023

  1. Slide 1: Q3'23 Financial Results Overview

    Agilent Technologies Q3’23 Financial Results Overview

  2. Slide 2: Safe Harbor

    Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth

  3. Slide 3: Agilent Results Q3'23

    Agilent Results Q3’23 A leading lab partner with unsurpassed capabilities and scale Q3’23 Financial Metrics Q3’23 Highlights • Revenues: $1.67B, -2.7% reported, • Growth: +2% growth ex-China with strength globally in our services offerings. -2.3% y/y core(1)(2) (-0.5% FX,+0.1% M&A). • Margins: Opera

  4. Slide 4: Growth in a $68B+ Market – Q3'23 Core Growth Results by End Market

    Growth in a $68B+ Market – Q3’23 Core Growth(2) Results by End Market Low single digit core growth ex-China, with Academia & Government continuing to see solid momentum  Pharma & Biopharma: Down -8% with BioPharma growth offset by softening global demand in small molecule, particularly in China  C

  5. Slide 5: Life Sciences & Applied Markets Group (LSAG)

    Life Sciences & Applied Markets Group (LSAG) • Macroeconomic uncertainty and a challenging comp Instrumentation, Informatics, and impacted Q3, however a healthy 5%+ 4-year CAGR for Consumables this business reflects the longer-term demand profile for for Analytical Laboratories our analytical instru

  6. Slide 6: Agilent CrossLab Group (ACG)

    Agilent CrossLab Group (ACG) Analytical Laboratory • CrossLab continued to deliver with another Services outstanding quarter in Q3, growing 11% core and achieving record 30%+ operating margins under challenging market conditions. • Delivered growth in every market and region during the quarter • Q3’

  7. Slide 7: Diagnostics and Genomics Group (DGG)

    Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Q3 core revenue growth of 3% was led by strong Nucleic Acid Manufacturing demand for our Pathology products as patients continue to return for regular health screening, as well as high-teens performance from NASD. • Started production i

  8. Slide 8: Q4'23 and FY'23 Guidance and Forward-looking Considerations

    Q4’23 and FY’23 Guidance and Forward-looking Considerations Based on Forecasted Currency Exchange Rates Q4’23 Guidance (1) FY’23 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,655 $1,705 Net Revenue ($M) $6,800 $6,850 Y/Y Core Revenue Growth (2) -12.2% -9.5% Y/Y Core Revenue Grow

  9. Slide 9: Q3'23 Financial Results Overview

    8/15/2023 Q3'23 Financial Results Overview

Agilent Technologies — Q3 2023 Earnings Presentation on 6ix